1 Despite advances in 3D printing techniques for optical t
2 Despite advances in active drug targeting for blood-brai
3 Despite advances in acute care, ischemic stroke remains
4 Despite advances in algorithms for segmenting nuclei for
5 Despite advances in allogeneic hematopoietic cell transp
6 Despite advances in AML research and treatment protocols
7 ve not recently been systematically assessed
despite advances in antiretroviral treatment (ART) poten
8 However,
despite advances in antithrombotic therapy, a fundamenta
9 Despite advances in antiviral chemotherapy, herpes simpl
10 However,
despite advances in AON chemistry and design, systemic u
11 Despite advances in ART that have transformed HIV into a
12 Despite advances in artificial intelligence (AI), its ap
13 Despite advances in asthma care, disparities persist.
14 Despite advances in asthma therapeutics, the burden rema
15 Despite advances in automated liquid handling and microf
16 Despite advances in automated species identification, tr
17 Despite advances in available immunosuppressive treatmen
18 Despite advances in bacterial genome engineering, delive
19 Despite advances in basic and translational research, th
20 Despite advances in betaIV-spectrin research in the nerv
21 Despite advances in both theoretical and empirical metho
22 Despite advances in breast cancer treatment, residual di
23 Despite advances in cancer genomics, radiotherapy is sti
24 Despite advances in cancer treatment over the past few d
25 Despite advances in cancer treatment, lifelong lymphoede
26 Despite advances in cardiac arrest treatment, high morta
27 ival following sudden cardiac arrest is poor
despite advances in cardiopulmonary resuscitation and th
28 Despite advances in care, mortality and morbidity remain
29 Despite advances in care, the mortality rate in patients
30 by cumulative toxicity and limited efficacy
despite advances in chemotherapeutic and radiotherapeuti
31 Despite advances in chemotherapy and vaccine development
32 Purpose
Despite advances in childhood cancer care, some patients
33 Despite advances in childhood pneumonia management, it r
34 Despite advances in clinical imaging, detection and quan
35 Despite advances in clinical management, 5-year survival
36 Despite advances in clinical management, there are curre
37 Thus,
despite advances in clinical practice, appropriate manag
38 Despite advances in clinical therapy, metastasis remains
39 Despite advances in combination chemotherapy, the overal
40 ients present with advanced disease in which
despite advances in combined modality therapy the outcom
41 Despite advances in complex wound management, appropriat
42 Despite advances in computational gene prediction algori
43 Despite advances in COVID-19 management, identifying pat
44 Despite advances in defining the critical molecular dete
45 Despite advances in detection and cytotoxic therapies, a
46 Despite advances in detection, comprehensive clinical, p
47 Despite advances in developing novel treatment modalitie
48 Despite advances in device design, there remains an appa
49 s anatomical challenges for successful TAVI,
despite advances in device design.
50 Despite advances in diabetic wound care, the significant
51 Despite advances in diagnosis and the use of different t
52 Despite advances in diagnosis and therapy, esophageal ad
53 onary embolism confers a high mortality rate
despite advances in diagnosis and therapy.
54 Despite advances in diagnosis and treatment, prostate ca
55 Despite advances in diagnosis and treatment, survival ra
56 Despite advances in diagnosis, smear microscopy insuffic
57 Despite advances in diagnostic techniques, it remains di
58 Despite advances in diagnostics, less than 5% of patient
59 Despite advances in directing the assembly of biomacromo
60 lence of human immunodeficiency virus (HIV),
despite advances in disease management and increasing an
61 Despite advances in DNA sequencing technology and expand
62 Despite advances in DNA sequencing technology, assembly
63 Despite advances in EFM computation, our review conclude
64 Despite advances in endovascular drug delivery, there is
65 Despite advances in formation of highly enantioenriched
66 Despite advances in genetic and proteomic techniques, a
67 Despite advances in genetic mapping of quantitative trai
68 Despite advances in GPCR crystallography, active state s
69 Despite advances in healthcare, stillbirth rates remain
70 reatment algorithms have been rewritten and,
despite advances in hematopoietic stem cell transplantat
71 Despite advances in high-throughput detection, the inert
72 Despite advances in high-throughput methods for discover
73 Despite advances in high-throughput methods, experimenta
74 Despite advances in high-throughput sequencing, marine m
75 Despite advances in HIV care, a subset of people with AH
76 Despite advances in HIV-1 prophylaxis, vertical transmis
77 Despite advances in hospital management in recent years,
78 Despite advances in human immunodeficiency virus (HIV) t
79 Despite advances in hydrogen atom transfer (HAT) catalys
80 However,
despite advances in identifying and characterizing CD133
81 Despite advances in identifying deafness genes, determin
82 odules on chest CT scans remain high at 50%,
despite advances in imaging technology and radiologist t
83 ese soft-tissue lesions remains problematic,
despite advances in imaging.
84 uences allograft function over the long term
despite advances in immunosuppression therapy.
85 Despite advances in immunosuppression, antibody-mediated
86 Despite advances in immunosuppression, long-term outcome
87 Despite advances in immunosuppressive therapies, the rat
88 Despite advances in interventional techniques, diabetes
89 ) and other rheumatic diseases remains poor,
despite advances in knowledge with regard to their patho
90 Despite advances in laboratory molecular-based detection
91 nonfunctional than functional variants and,
despite advances in large-scale DNA synthesis, individua
92 Despite advances in lithotripsy technology, bleeding con
93 Despite advances in live animal imaging with PAT, there
94 Despite advances in macromolecular structure determinati
95 nd mortality in critically ill patients, and
despite advances in management, mortality remains high.
96 Despite advances in management, VGF remains one of the l
97 Despite advances in mechanical circulatory devices and p
98 Despite advances in mechanical ventilation for ARDS, man
99 is a major cause of morbidity and mortality
despite advances in medical and device therapy.
100 sease (CD) patients is still currently valid
despite advances in medical and surgical treatments.
101 Despite advances in medical care, preterm birth and its
102 Despite advances in medical device fabrication and antim
103 Despite advances in medical management, the survival rat
104 mortality for UC has doubled in recent years
despite advances in medical management.
105 Despite advances in medical therapies to help prevent th
106 Despite advances in medical therapy and percutaneous rev
107 Despite advances in medical therapy, congestive heart fa
108 Despite advances in medical therapy, HF continues to be
109 Despite advances in medical therapy, liver replacement c
110 c death remains a leading cause of mortality
despite advances in medical treatment for the prevention
111 Despite advances in medical, percutaneous, and surgical
112 he general population is still not confirmed
despite advances in medicine.
113 Despite advances in metabolite profiling, a full picture
114 Despite advances in methods to detect protein synthesis,
115 Despite advances in modeling the risks of this toxic and
116 Despite advances in modern medicine, there are few optio
117 Despite advances in molecular diagnostics, the ability t
118 Despite advances in monitoring spatiotemporal expression
119 PURPOSE OF REVIEW:
Despite advances in multimodality therapy, the overall 5
120 Despite advances in multimodality therapy, the prognosis
121 wn to the nanoscale has remained challenging
despite advances in nano-optics and nanomaterials.
122 Despite advances in nanotechnology, we still lack the ab
123 However,
despite advances in nanowire synthesis, progress towards
124 Despite advances in network science and risk analysis, w
125 Despite advances in neurobiological understanding of res
126 Despite advances in neuroimaging, there are currently li
127 Despite advances in next-generation sequencing (NGS) and
128 Despite advances in obstetrics and neonatology, the rate
129 Despite advances in OCTA technology, inconsistencies in
130 Despite advances in oncology drug development, most comm
131 Despite advances in operative technique and perioperativ
132 horacic and thoracoabdominal aortic aneurysm
despite advances in operative technique.
133 Despite advances in organometallic cross-coupling of alk
134 Despite advances in our understanding and management of
135 Despite advances in our understanding of E7, reagents th
136 Yet
despite advances in our understanding of evolution, what
137 Despite advances in our understanding of GRP78 actions,
138 Despite advances in our understanding of mechano- and th
139 causes of morbidity and mortality worldwide
despite advances in our understanding of pathophysiology
140 Yet,
despite advances in our understanding of productivity at
141 Despite advances in our understanding of the disease, B.
142 Despite advances in our understanding of the mechanisms
143 itherto defied all attempts at reproduction,
despite advances in our understanding of the molecular m
144 se has undergone little change in many years
despite advances in our understanding of the pathogenesi
145 Despite advances in our understanding of the ways in whi
146 patients with encephalitis has remained poor
despite advances in pathogen-specific testing such as PC
147 Despite advances in perioperative care of the recipient,
148 y suffer substantial morbidity and mortality
despite advances in perioperative care, whereas patients
149 ing cause of global morbidity and mortality,
despite advances in pharmacological and surgical interve
150 Despite advances in pharmacological treatments aimed at
151 Despite advances in pharmacotherapy and stents, reinfarc
152 Despite advances in physicochemical remediation technolo
153 Despite advances in plant seed metabolomics, knowledge a
154 Despite advances in prevention and treatment, sexually t
155 Despite advances in prevention, detection, and treatment
156 Despite advances in preventive strategies, cytomegalovir
157 Despite advances in preventive, diagnostic, and therapeu
158 Despite advances in promoting axonal regeneration after
159 Despite advances in prophylaxis and treatment, cytomegal
160 Despite advances in quantitative biology, full parameter
161 Despite advances in quantitative ocular imaging and peri
162 Despite advances in rapid analysis, the utility of matri
163 Despite advances in recent methods conducted on large da
164 Despite advances in renal replacement therapy, the morta
165 Despite advances in renovascular disease (RVD) research,
166 Despite advances in reperfusion and mechanical circulato
167 Despite advances in reperfusion therapy, acute coronary
168 Despite advances in resolution accompanying the developm
169 Despite advances in resting state functional magnetic re
170 out-of-hospital cardiac arrest remains high
despite advances in resuscitation and early revasculariz
171 Despite advances in resuscitation care in recent years,
172 Despite advances in resuscitation methods, survival afte
173 Despite advances in resuscitation science, basic life su
174 Despite advances in resuscitation science, basic life su
175 Despite advances in rheumatoid arthritis (RA) treatment,
176 n rheumatoid arthritis has remained stagnant
despite advances in rheumatoid arthritis and heart failu
177 Despite advances in ribosome structural biology, identif
178 Despite advances in robotic-assisted surgery (RAS) in th
179 Despite advances in sampling and scoring strategies, Mon
180 Despite advances in search technology, users prefer retr
181 Despite advances in sequence-based microbial profiling a
182 Despite advances in sequencing technologies, assembly of
183 Despite advances in sequencing technology, discovering r
184 f bacterial genomes remains labor-intensive,
despite advances in sequencing technology.
185 Despite advances in sequencing, the goal of obtaining a
186 Despite advances in shotgun whole-genome metagenomic met
187 Despite advances in single-molecule characterization and
188 te for the detection of obstructive CAD and,
despite advances in SPECT technology, remains superior.
189 Despite advances in stem cell research, cell transplanta
190 ion (PCI) for ACS remains a clinical problem
despite advances in stent technology in both bare-metal
191 Despite advances in support and the development of novel
192 th unacceptably high morbidity and mortality
despite advances in supportive care measures and bacteri
193 Despite advances in supportive care, fulminant-phase inh
194 Despite advances in supportive therapy to prevent compli
195 Despite advances in surgery and radiation, most malignan
196 Despite advances in surgery, imaging, chemotherapy, and
197 Despite advances in surgery, radiation therapy, and chem
198 as not significantly changed in two decades,
despite advances in surgery, radiation, and chemotherapy
199 Despite advances in surgery, radiotherapy, and chemother
200 Despite advances in surgical and medical management of p
201 Despite advances in surgical and medical therapies, appr
202 Despite advances in surgical and percutaneous coronary r
203 Despite advances in surgical chemotherapeutic and radiot
204 male cancer-related morbidity and mortality,
despite advances in surgical management and innovations
205 f lost periodontium remains an elusive goal,
despite advances in surgical procedures and materials.
206 Despite advances in surgical technique and material, pos
207 Despite advances in surgical technique and multimodality
208 duodenal cancer mortality rates remain high
despite advances in surgical technique, perioperative ca
209 Despite advances in surgical techniques and critical car
210 Despite advances in T-cell immunotherapy against Epstein
211 Despite advances in targeted anticancer therapies, there
212 Despite advances in the biotechnological exploitation of
213 Despite advances in the chemical synthesis of alpha-syn
214 Despite advances in the clinical utility and reliability
215 Despite advances in the curative treatment of acute myel
216 Despite advances in the detection and therapy of colorec
217 Despite advances in the diagnosis and management of idio
218 Despite advances in the diagnosis and treatment of Clost
219 Despite advances in the diagnosis and treatment of IR, n
220 Despite advances in the diagnosis and treatment of SAH,
221 Despite advances in the differentiation of insulin-produ
222 Despite advances in the field of lung transplantation, t
223 Despite advances in the field, the development of precis
224 Despite advances in the gene annotation process, the fun
225 Despite advances in the gene-set enrichment analysis met
226 Despite advances in the identification of ASD risk genes
227 Despite advances in the identification of genomic and mo
228 Despite advances in the identification of intermediates,
229 Despite advances in the identification of lymphoid-restr
230 Despite advances in the identification of novel gene mut
231 Despite advances in the management of myeloablative allo
232 Despite advances in the management of non-small-cell lun
233 Despite advances in the management of osteosarcoma (OSA)
234 Despite advances in the management of rectal cancer, loc
235 Despite advances in the management of sepsis and acute r
236 Despite advances in the management of sickle cell diseas
237 Despite advances in the management of this disease, the
238 Despite advances in the methods for discovery of putativ
239 Despite advances in the miniaturization of solid-phase e
240 Despite advances in the molecular biology of cardiac myo
241 Despite advances in the molecular epidemiology of C. neo
242 Despite advances in the molecular genetics of these two
243 Despite advances in the molecular pathogenesis of gliobl
244 Despite advances in the pathologic understanding of eosi
245 ldren and adolescents with rheumatic disease
despite advances in the pharmacological management of th
246 Despite advances in the prophylaxis and acute treatment
247 Despite advances in the sensitivity of silicon photonic
248 Despite advances in the standardization of quantitative
249 Despite advances in the study of molecular biology of ca
250 Despite advances in the systemic treatment of patients w
251 Despite advances in the therapeutic use of recombinant g
252 Despite advances in the treatment of asthma, optimizatio
253 Despite advances in the treatment of bipolar disorder, a
254 Despite advances in the treatment of diabetes mellitus,
255 Despite advances in the treatment of HIV, HIV-infected p
256 Despite advances in the treatment of schizophrenia spect
257 Despite advances in the understanding of pathways regula
258 Despite advances in therapeutics, renal damage in partic
259 Despite advances in therapy for heart failure, improveme
260 Despite advances in therapy for melanoma, heterogeneous
261 Despite advances in therapy, glioblastoma remains an inc
262 Despite advances in therapy, many patients with systemic
263 Despite advances in therapy, morbidity and mortality fro
264 Despite advances in therapy, nearly 30% of children with
265 Despite advances in therapy, patients with a histologic
266 Despite advances in therapy, patients with a histologic
267 remains a substantial and increasing problem
despite advances in therapy.
268 Despite advances in this area, further research is neede
269 Despite advances in treatment and prognosis of non-small
270 g retinoblastoma with seeding is challenging
despite advances in treatment modalities.
271 Despite advances in treatment of both cardiovascular and
272 Despite advances in treatment of DKA, the pathogenesis o
273 Despite advances in treatment strategies for hepatitis C
274 Despite advances in treatment, including the introductio
275 CLL) is the most common adult leukemia, but,
despite advances in treatment, many patients still exper
276 Despite advances in treatment, mortality in acute myocar
277 Despite advances in treatment, there was little evidence
278 Despite advances in treatment, up to 30% of women eventu
279 e higher mortality rates than White patients
despite advances in treatment.
280 Despite advances in trimer design, the roots of Env trim
281 Despite advances in understanding how ATM signals cell c
282 Despite advances in understanding its immunopathogenesis
283 However,
despite advances in understanding murine Th17 differenti
284 Despite advances in understanding of ALS disease progres
285 Despite advances in understanding of the disease, it rem
286 Despite advances in understanding systemic lupus erythem
287 Despite advances in understanding the cell biology of gl
288 major challenges in diagnosis and management
despite advances in understanding the epidemiology, micr
289 Despite advances in understanding the genetic and biophy
290 Despite advances in understanding the molecular basis of
291 stress have recently been demonstrated, but
despite advances in understanding the pathogenesis, ther
292 Despite advances in understanding the pathophysiology of
293 Despite advances in understanding the pathophysiology of
294 Despite advances in understanding the patterns and proce
295 Despite advances in understanding the role of histone de
296 ment in outcomes seen in more than 2 decades
despite advances in upfront therapy and improved surviva
297 Despite advances in urban ecology, we do not adequately
298 Despite advances in vaccine development, it remains uncl
299 Despite advances in ventilatory management, FC remains a
300 Despite advances in X-ray information, the organization